Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease : A Report of the Cure Glomerulonephropathy Study
Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved..
RATIONALE & OBJECTIVE: Patients with glomerular disease (GN) may be at increased risk of severe COVID-19, yet concerns over vaccines causing disease relapse may lead to vaccine hesitancy. We examined the associations of COVID-19 with longitudinal kidney function and proteinuria and compared these with similar associations with COVID-19 vaccination.
STUDY DESIGN: Observational cohort study from July 1, 2021, to January 1, 2023.
SETTING & PARTICIPANTS: A prospective observational study network of 71 centers from North America and Europe (CureGN) with children and adults with primary minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy.
EXPOSURE: COVID-19 and COVID-19 vaccination.
OUTCOME: Repeated measure of estimated glomerular filtration rate (eGFR); recurrent time-to-event outcome of GN disease worsening as defined by doubling of the urinary protein-creatinine ratio (UPCR) to at least 1.5g/g or increase in dipstick urine protein by 2 ordinal levels to 3+(300mg/dL) or above.
ANALYTICAL APPROACH: Interrupted time series analysis for eGFR. Prognostic matched sequential stratification recurrent event analysis for GN disease worsening.
RESULTS: Among 2,055 participants, 722 (35%) reported COVID-19 infection; of these, 92 (13%) were hospitalized, and 3 died (<1%). The eGFR slope before COVID-19 infection was-1.40mL/min/1.73m2 (± 0.29 SD); within 6 months after COVID-19 infection, the eGFR slope was-4.26mL/min/1.73m2 (± 3.02 SD), which was not significantly different (P=0.34). COVID-19 was associated with increased risk of worsening GN disease activity (HR, 1.35 [95% CI, 1.01-1.80]). Vaccination was not associated with a change in eGFR (-1.34mL/min/1.73m2±0.15 SD vs-2.16mL/min/1.73m2±1.74 SD; P=0.6) or subsequent GN disease worsening (HR 1.02 [95% CI, 0.79-1.33]) in this cohort.
LIMITATIONS: Infrequent or short follow-up.
CONCLUSIONS: Among patients with primary GN, COVID-19 infection was severe for 1 in 8 cases and was associated with subsequent worsening of GN disease activity, as defined by proteinuria. By contrast, vaccination against COVID-19 was not associated with change in disease activity or kidney function decline. These results support COVID-19 vaccination for patients with GN.
PLAIN-LANGUAGE SUMMARY: In this cohort study of 2,055 patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy, COVID-19 resulted in hospitalization or death for 1 in 8 cases and was associated with a 35% increase in risk for worsening proteinuria. By contrast, vaccination did not appear to adversely affect kidney function or proteinuria. Our data support vaccination for COVID-19 in patients with glomerular disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
American journal of kidney diseases : the official journal of the National Kidney Foundation - 83(2024), 1 vom: 06. Jan., Seite 37-46 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Chia-Shi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.12.2023 Date Revised 07.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.ajkd.2023.07.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36155401X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36155401X | ||
| 003 | DE-627 | ||
| 005 | 20240207232035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.ajkd.2023.07.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM36155401X | ||
| 035 | |a (NLM)37657635 | ||
| 035 | |a (PII)S0272-6386(23)00773-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Chia-Shi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease |b A Report of the Cure Glomerulonephropathy Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2023 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a RATIONALE & OBJECTIVE: Patients with glomerular disease (GN) may be at increased risk of severe COVID-19, yet concerns over vaccines causing disease relapse may lead to vaccine hesitancy. We examined the associations of COVID-19 with longitudinal kidney function and proteinuria and compared these with similar associations with COVID-19 vaccination | ||
| 520 | |a STUDY DESIGN: Observational cohort study from July 1, 2021, to January 1, 2023 | ||
| 520 | |a SETTING & PARTICIPANTS: A prospective observational study network of 71 centers from North America and Europe (CureGN) with children and adults with primary minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy | ||
| 520 | |a EXPOSURE: COVID-19 and COVID-19 vaccination | ||
| 520 | |a OUTCOME: Repeated measure of estimated glomerular filtration rate (eGFR); recurrent time-to-event outcome of GN disease worsening as defined by doubling of the urinary protein-creatinine ratio (UPCR) to at least 1.5g/g or increase in dipstick urine protein by 2 ordinal levels to 3+(300mg/dL) or above | ||
| 520 | |a ANALYTICAL APPROACH: Interrupted time series analysis for eGFR. Prognostic matched sequential stratification recurrent event analysis for GN disease worsening | ||
| 520 | |a RESULTS: Among 2,055 participants, 722 (35%) reported COVID-19 infection; of these, 92 (13%) were hospitalized, and 3 died (<1%). The eGFR slope before COVID-19 infection was-1.40mL/min/1.73m2 (± 0.29 SD); within 6 months after COVID-19 infection, the eGFR slope was-4.26mL/min/1.73m2 (± 3.02 SD), which was not significantly different (P=0.34). COVID-19 was associated with increased risk of worsening GN disease activity (HR, 1.35 [95% CI, 1.01-1.80]). Vaccination was not associated with a change in eGFR (-1.34mL/min/1.73m2±0.15 SD vs-2.16mL/min/1.73m2±1.74 SD; P=0.6) or subsequent GN disease worsening (HR 1.02 [95% CI, 0.79-1.33]) in this cohort | ||
| 520 | |a LIMITATIONS: Infrequent or short follow-up | ||
| 520 | |a CONCLUSIONS: Among patients with primary GN, COVID-19 infection was severe for 1 in 8 cases and was associated with subsequent worsening of GN disease activity, as defined by proteinuria. By contrast, vaccination against COVID-19 was not associated with change in disease activity or kidney function decline. These results support COVID-19 vaccination for patients with GN | ||
| 520 | |a PLAIN-LANGUAGE SUMMARY: In this cohort study of 2,055 patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy, COVID-19 resulted in hospitalization or death for 1 in 8 cases and was associated with a 35% increase in risk for worsening proteinuria. By contrast, vaccination did not appear to adversely affect kidney function or proteinuria. Our data support vaccination for COVID-19 in patients with glomerular disease | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccines | |
| 650 | 4 | |a IgA glomerulonephritis | |
| 650 | 4 | |a focal segmental glomerulosclerosis | |
| 650 | 4 | |a glomerular filtration rate | |
| 650 | 4 | |a glomerulonephritis | |
| 650 | 4 | |a lipoid nephrosis | |
| 650 | 4 | |a membranous glomerulonephritis | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Glenn, Dorey A |e verfasserin |4 aut | |
| 700 | 1 | |a Helmuth, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Abigail R |e verfasserin |4 aut | |
| 700 | 1 | |a Bomback, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Canetta, Pietro A |e verfasserin |4 aut | |
| 700 | 1 | |a Coppock, Gaia M |e verfasserin |4 aut | |
| 700 | 1 | |a Khalid, Myda |e verfasserin |4 aut | |
| 700 | 1 | |a Tuttle, Katherine R |e verfasserin |4 aut | |
| 700 | 1 | |a Bou-Matar, Raed |e verfasserin |4 aut | |
| 700 | 1 | |a Greenbaum, Larry A |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Bruce M |e verfasserin |4 aut | |
| 700 | 1 | |a Holzman, Lawrence B |e verfasserin |4 aut | |
| 700 | 1 | |a Smoyer, William E |e verfasserin |4 aut | |
| 700 | 1 | |a Rheault, Michelle N |e verfasserin |4 aut | |
| 700 | 1 | |a Gipson, Debbie |e verfasserin |4 aut | |
| 700 | 1 | |a Mariani, Laura H |e verfasserin |4 aut | |
| 700 | 0 | |a Cure Glomerulonephropathy (CureGN) Study Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Wooin |e investigator |4 oth | |
| 700 | 1 | |a Appel, Gerald |e investigator |4 oth | |
| 700 | 1 | |a Appelbaum, Paul |e investigator |4 oth | |
| 700 | 1 | |a Babayev, Revekka |e investigator |4 oth | |
| 700 | 1 | |a Chan, Brenda |e investigator |4 oth | |
| 700 | 1 | |a D'Agati, Vivette Denise |e investigator |4 oth | |
| 700 | 1 | |a Dogra, Samitri |e investigator |4 oth | |
| 700 | 1 | |a Fernandez, Hilda |e investigator |4 oth | |
| 700 | 1 | |a Gharavi, Ali |e investigator |4 oth | |
| 700 | 1 | |a Hines, William |e investigator |4 oth | |
| 700 | 1 | |a Husain, Syed Ali |e investigator |4 oth | |
| 700 | 1 | |a Jain, Namrata |e investigator |4 oth | |
| 700 | 1 | |a Kiryluk, Krzysztof |e investigator |4 oth | |
| 700 | 1 | |a Lin, Fangming |e investigator |4 oth | |
| 700 | 1 | |a Marasa, Maddalena |e investigator |4 oth | |
| 700 | 1 | |a Markowitz, Glen |e investigator |4 oth | |
| 700 | 1 | |a Rasouly, Hila Milo |e investigator |4 oth | |
| 700 | 1 | |a Mohan, Sumit |e investigator |4 oth | |
| 700 | 1 | |a Mongera, Nicola |e investigator |4 oth | |
| 700 | 1 | |a Nestor, Jordan |e investigator |4 oth | |
| 700 | 1 | |a Nickolas, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Radhakrishnan, Jai |e investigator |4 oth | |
| 700 | 1 | |a Rao, Maya |e investigator |4 oth | |
| 700 | 1 | |a Sanna-Cherchi, Simone |e investigator |4 oth | |
| 700 | 1 | |a Shirazian, Shayan |e investigator |4 oth | |
| 700 | 1 | |a Stokes, Michael Barry |e investigator |4 oth | |
| 700 | 1 | |a Uy, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Valeri, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Vena, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Foroncewicz, Bartosz |e investigator |4 oth | |
| 700 | 1 | |a Moszczuk, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Mucha, Krzysztof |e investigator |4 oth | |
| 700 | 1 | |a Perkowska-Ptasińska, Agnieszka |e investigator |4 oth | |
| 700 | 1 | |a Ghiggeri, Gian Marco |e investigator |4 oth | |
| 700 | 1 | |a Lugani, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Ambruzs, Josephine |e investigator |4 oth | |
| 700 | 1 | |a Liapis, Helen |e investigator |4 oth | |
| 700 | 1 | |a Baracco, Rossana |e investigator |4 oth | |
| 700 | 1 | |a Jain, Amrish |e investigator |4 oth | |
| 700 | 1 | |a Isa Ashoor |e investigator |4 oth | |
| 700 | 1 | |a Aviles, Diego |e investigator |4 oth | |
| 700 | 1 | |a Srivastava, Tarak |e investigator |4 oth | |
| 700 | 1 | |a Ahn, Sun-Young |e investigator |4 oth | |
| 700 | 1 | |a Devarajan, Prasad |e investigator |4 oth | |
| 700 | 1 | |a Erkan, Elif |e investigator |4 oth | |
| 700 | 1 | |a Claes, Donna |e investigator |4 oth | |
| 700 | 1 | |a Stone, Hillarey |e investigator |4 oth | |
| 700 | 1 | |a Mason, Sherene |e investigator |4 oth | |
| 700 | 1 | |a Gbadegesin, Rasheed |e investigator |4 oth | |
| 700 | 1 | |a Gomez-Mendez, Liliana |e investigator |4 oth | |
| 700 | 1 | |a Yin, Hong Julie |e investigator |4 oth | |
| 700 | 1 | |a Cai, Yi |e investigator |4 oth | |
| 700 | 1 | |a Jens, Goebel |e investigator |4 oth | |
| 700 | 1 | |a Steinke, Julia |e investigator |4 oth | |
| 700 | 1 | |a Weaver, Donald |e investigator |4 oth | |
| 700 | 1 | |a Lane, Jerome |e investigator |4 oth | |
| 700 | 1 | |a Cramer, Carl |e investigator |4 oth | |
| 700 | 1 | |a Pan, Cindy |e investigator |4 oth | |
| 700 | 1 | |a Paloian, Neil |e investigator |4 oth | |
| 700 | 1 | |a Sreedharan, Rajasree |e investigator |4 oth | |
| 700 | 1 | |a Selewski, David |e investigator |4 oth | |
| 700 | 1 | |a Twombley, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Bowers, Corinna |e investigator |4 oth | |
| 700 | 1 | |a Dreher, Mary |e investigator |4 oth | |
| 700 | 1 | |a Kallash, Mahmoud |e investigator |4 oth | |
| 700 | 1 | |a Mahan, John |e investigator |4 oth | |
| 700 | 1 | |a Sharpe, Samantha |e investigator |4 oth | |
| 700 | 1 | |a Al-Uzri, Amira |e investigator |4 oth | |
| 700 | 1 | |a Iragorri, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Belsha, Craig |e investigator |4 oth | |
| 700 | 1 | |a Alge, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Braun, Michael |e investigator |4 oth | |
| 700 | 1 | |a Gomez, A C |e investigator |4 oth | |
| 700 | 1 | |a Wenderfer, Scott |e investigator |4 oth | |
| 700 | 1 | |a Vasylyeva, Tetyana |e investigator |4 oth | |
| 700 | 1 | |a Feig, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Fuentes, Gabriel Cara |e investigator |4 oth | |
| 700 | 1 | |a Hannah, Melisha |e investigator |4 oth | |
| 700 | 1 | |a Nester, Carla |e investigator |4 oth | |
| 700 | 1 | |a Chishti, Aftab |e investigator |4 oth | |
| 700 | 1 | |a Klein, Jon |e investigator |4 oth | |
| 700 | 1 | |a Katsoufis, Chryso |e investigator |4 oth | |
| 700 | 1 | |a Seeherunvong, Wacharee |e investigator |4 oth | |
| 700 | 1 | |a Wong, Craig |e investigator |4 oth | |
| 700 | 1 | |a Mathews, Nisha |e investigator |4 oth | |
| 700 | 1 | |a Barcia, John |e investigator |4 oth | |
| 700 | 1 | |a Swiatecka-Urban, Agnes |e investigator |4 oth | |
| 700 | 1 | |a Bartosh, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Hunley, Tracy |e investigator |4 oth | |
| 700 | 1 | |a Dharnidharka, Vikas |e investigator |4 oth | |
| 700 | 1 | |a Gaut, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Laurin, Louis-Philippe |e investigator |4 oth | |
| 700 | 1 | |a Royal, Virginie |e investigator |4 oth | |
| 700 | 1 | |a Achanti, Anand |e investigator |4 oth | |
| 700 | 1 | |a Budisavljevic, Milos |e investigator |4 oth | |
| 700 | 1 | |a Self, Sally |e investigator |4 oth | |
| 700 | 1 | |a Ghossein, Cybele |e investigator |4 oth | |
| 700 | 1 | |a Peleg, Yonatan |e investigator |4 oth | |
| 700 | 1 | |a Wadhwani, Shikha |e investigator |4 oth | |
| 700 | 1 | |a Almaani, Salem |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of kidney diseases : the official journal of the National Kidney Foundation |d 1982 |g 83(2024), 1 vom: 06. Jan., Seite 37-46 |w (DE-627)NLM012600814 |x 1523-6838 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:1 |g day:06 |g month:01 |g pages:37-46 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.ajkd.2023.07.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 1 |b 06 |c 01 |h 37-46 | ||